The materials for DUPIXENT contained in this virtual exhibition are approved for use only in the United States of America. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the full Prescribing Information and/or the Summary of Product Characteristics (SmPC).
Many patients. one dupixent.
DUPIXENT offers a unique mechanism of action that may help control Type 2 inflammation in 3 approved indications1,a
a The mechanism of dupilumab action in asthma has not been established.
EXPLORE THE ONLY BIOLOGIC TO INHIBIT BOTH IL-4 AND IL-13 SIGNALING IN 3 INDICATIONS1
CRSwNP, chronic rhinosinusitis with nasal polyposis.
References: 1. DUPIXENT Prescribing Information. 2. Data on file, Sanofi US. IQVIA Patient Insights; data through September 2020.